{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:22:10Z","timestamp":1791994930596,"version":"4.4.0"},"reference-count":66,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.2217\/14622416.6.7.755","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T10:56:30Z","timestamp":1133434590000},"page":"756-775","source":"Crossref","is-referenced-by-count":18,"title":["OASIS-HT: Design of a Pharmacogenomic Dose-Finding Study"],"prefix":"10.1080","volume":"6","author":[{"given":"Jan A","family":"Staessen","sequence":"first","affiliation":[{"name":"Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kuznetsova","sequence":"additional","affiliation":[{"name":"Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rok","family":"Acceto","sequence":"additional","affiliation":[{"name":"Hypertension Department, University Medical Centre,  Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Bacchieri","sequence":"additional","affiliation":[{"name":"Sigma Tau Industrie Farmaceutiche Reunite,  Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine D, University Hospital of M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Burnier","sequence":"additional","affiliation":[{"name":"Division of Hypertension and Cardiovascular Medicine, Centre Hospitalier Universitaire Vaudois,  Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Celis","sequence":"additional","affiliation":[{"name":"Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Citterio","sequence":"additional","affiliation":[{"name":"Divisione di Nefrologia Dialisi e Ipertensione, Ospedale San Raffaele, Dipartimento di Scienze e Techologie Biomediche, Universit\u00e1 Vita-Salute,  Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W","family":"de Leeuw","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospital of Maastricht,  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Filipovsk\u00fd","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, Charles University,  Pilsen, The Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Centre Hospitalier Universitaire,  Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalina","family":"Kawecka-Jaszcz","sequence":"additional","affiliation":[{"name":"First Cardiac Department, Jagiellonian University,  Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manunta","sequence":"additional","affiliation":[{"name":"Divisione di Nefrologia Dialisi e Ipertensione, Ospedale San Raffaele, Dipartimento di Scienze e Techologie Biomediche, Universit\u00e1 Vita-Salute,  Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Nikitin","sequence":"additional","affiliation":[{"name":"Institute of Internal Medicine,  Novosibirsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin T","family":"O'Brien","sequence":"additional","affiliation":[{"name":"ADAPT Centre and Blood Pressure Unit, Beaumont Hospital and Department of Clinical Pharmacology, Royal College of Surgeons in Ireland,  Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Red\u00f3n","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario Valencia, University of Valencia , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutgarde","family":"Thijs","sequence":"additional","affiliation":[{"name":"Study Coordinating Centre, Hypertension and Cardiovascular Rehabilitation Unit, Department of Molecular and Cardiovascular Research, University of Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Prassis Research Institute,  Settimo Milanese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Valentini","sequence":"additional","affiliation":[{"name":"Sigma Tau Industrie Farmaceutiche Reunite,  Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Divisione di Nefrologia Dialisi e Ipertensione, Ospedale San Raffaele, Dipartimento di Scienze e Techologie Biomediche, Universit\u00e1 Vita-Salute,  Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2005,10,5]]},"reference":[{"key":"e_1_3_2_3_1","first-page":"187","volume-title":"Acta Physiol. Scand.","author":"Ferrandi M","year":"2000","unstructured":"Ferrandi M , BianchiG: Genetic mechanisms underlying the regulation of urinary sodium excretion and arterial blood pressure: the role of adducin. Acta Physiol. Scand.168, 187\u2013193 (2000)."},{"key":"e_1_3_2_4_1","first-page":"884","volume-title":"Cell. Mol. Life Sci.","author":"Matsuoka Y","year":"2000","unstructured":"Matsuoka Y , LiX, BennettV: Adducin: structure, function and regulation. Cell. Mol. Life Sci.57, 884\u2013895 (2000)."},{"key":"e_1_3_2_5_1","first-page":"3999","volume-title":"Proc. Natl Acad. Sci. USA","author":"Bianchi G","year":"1994","unstructured":"Bianchi G , TripodiG, CasariG et al.: Two point mutations within the adducin genes are involved in blood pressure variation: Proc. Natl Acad. Sci. USA91, 3999\u20134003 (1994)."},{"key":"e_1_3_2_6_1","first-page":"2815","volume-title":"J. Clin. Invest.","author":"Tripodi G","year":"1996","unstructured":"Tripodi G , ValtortaF, TorielliL et al.: Hypertension-associated point mutations in the adducin \u03b1 and \u03b2 subunits affect actin cytoskeleton and ion transport. J. Clin. Invest.97, 2815\u20132822 (1996)."},{"key":"e_1_3_2_7_1","first-page":"1083","volume-title":"Kidney Int.","author":"Barlassina C","year":"2000","unstructured":"Barlassina C , SchorkNJ, ManutaP et al.: Synergistic effect of \u03b1-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int.57, 1083\u20131090 (2000)."},{"key":"e_1_3_2_8_1","first-page":"1349","volume-title":"J. Hypertens.","author":"Staessen JA","year":"2001","unstructured":"Staessen JA , WangJG, BrandE et al.: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens.19, 1349\u20131358 (2001)."},{"key":"e_1_3_2_9_1","first-page":"1158","volume-title":"Am. J. Kidney Dis.","author":"Wang JG","year":"2001","unstructured":"Wang JG , StaessenJA, TizzoniL et al.: Renal function in relation to three candidate genes. Am. J. Kidney Dis.38, 1158\u20131168 (2001)."},{"key":"e_1_3_2_10_1","first-page":"F182","volume-title":"Am. J. Physiol.","author":"De Angelis C","year":"1998","unstructured":"De Angelis C , HaupertGT Jr: Hypoxia triggers release of an endogenous inhibitor of Na+-K+-ATPase from midbrain and adrenal. Am. J. Physiol.274, F182\u2013F188 (1998)."},{"key":"e_1_3_2_11_1","first-page":"1181","volume-title":"J. Hypertens.","author":"Rossi G","year":"1995","unstructured":"Rossi G , ManuntaP, HamlynJM et al.: Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J. Hypertens.13, 1181\u20131191 (1995)."},{"key":"e_1_3_2_12_1","first-page":"198","volume-title":"Hypertension","author":"Manunta P","year":"2001","unstructured":"Manunta P , MessaggioE, BallabeniC et al.: Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension38, 198\u2013203 (2001)."},{"key":"e_1_3_2_13_1","first-page":"C511","volume-title":"Am. J. Physiol.","author":"Orlov SN","year":"1999","unstructured":"Orlov SN , AdragnaNC, AdarichevVA, HametP: Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. Am. J. Physiol.276, C511-C536 (1999)."},{"key":"e_1_3_2_14_1","first-page":"2440","volume-title":"Eur. J. Biochem.","author":"Schoner W","year":"2002","unstructured":"Schoner W : Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem.269, 2440\u20132448 (2002)."},{"key":"e_1_3_2_15_1","first-page":"1821","volume-title":"Science","author":"Anderson RGW","year":"2002","unstructured":"Anderson RGW , JacobsonK: A role for lipid shells in targeting proteins to caveolae, raft, and other lipid domains. Science296, 1821\u20131825 (2002)."},{"key":"e_1_3_2_16_1","first-page":"1475","volume-title":"J. Hypertens.","author":"Wang JG","year":"2003","unstructured":"Wang JG , StaessenJA, MessaggioE et al.: Salt, endogenous ouabain and blood pressure in the general population. J. Hypertens.21, 1475\u20131481 (2003)."},{"key":"e_1_3_2_17_1","first-page":"1561","volume-title":"J. Med. Chem.","author":"Quadri L","year":"1997","unstructured":"Quadri L , BianchiG, CerriA et al.: 17\u03b2-(3-furyl)-5\u03b2-androstane-3\u03b2,14\u03b2,17\u03b1-triol (PST 2238). A very potent antihypertensive with a novel mechanism of action. J. Med. Chem.40, 1561\u20131564 (1997)."},{"key":"e_1_3_2_18_1","first-page":"1074","volume-title":"J. Pharmacol. Exp. Ther.","author":"Ferrari P","year":"1999","unstructured":"Ferrari P , FerrandiM, TripodiG et al.: PST 2238: a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J. Pharmacol. Exp. Ther.288, 1074\u20131083 (1999)."},{"key":"e_1_3_2_19_1","first-page":"33306","volume-title":"J. Biol. Chem.","author":"Ferrandi M","year":"2004","unstructured":"Ferrandi M , MolinariI, BarassiP, MinottiE, BianchiG, FerrariP: Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST2238. J. Biol. Chem.279, 33306\u201333314 (2004)."},{"key":"e_1_3_2_20_1","first-page":"39","volume-title":"Cardiovasc. Drug Rev.","author":"Ferrari P","year":"1999","unstructured":"Ferrari P , FerrandiM, TorielliL, TripodiG, MelloniP, BianchiG: PST2238. a new antihypertensive compound that modulates Na+,K+-ATPase and antagonizes the pressor effect of OLF. Cardiovasc. Drug Rev.17, 39\u201357 (1999)."},{"key":"e_1_3_2_21_1","first-page":"1011","volume-title":"J. Hypertens.","year":"2003","unstructured":"European Society of Hypertension\/European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension\/European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J. Hypertens.21, 1011\u20131053 (2003)."},{"key":"e_1_3_2_22_1","first-page":"565","volume-title":"Circulation","author":"Casale PN","year":"1987","unstructured":"Casale PN , DevereuxRB, AlonsoDR, CampoE, KligfieldP: Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation75, 565\u2013572 (1987)."},{"key":"e_1_3_2_23_1","first-page":"417","volume-title":"J. Am. Coll. Cardiol","author":"Okin PM","year":"1995","unstructured":"Okin PM , RomanMJ, DevereuxRB, KligfieldP: Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J. Am. Coll. Cardiol. 25, 417\u2013423 (1995)."},{"key":"e_1_3_2_24_1","first-page":"161","volume-title":"Am. Heart. J.","author":"Sokolow M","year":"1949","unstructured":"Sokolow M , LyonTP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart. J.37, 161\u2013186 (1949)."},{"key":"e_1_3_2_25_1","first-page":"821","volume-title":"J. Hypertens.","author":"O'Brien E","year":"2003","unstructured":"O'Brien E , AsmarR, BeilinL et al.: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens.21, 821\u2013848 (2003)."},{"key":"e_1_3_2_26_1","first-page":"3","volume-title":"Blood Press. Monit.","author":"O'Brien E","year":"2002","unstructured":"O'Brien E , PickeringT, AsmarR et al.: Working group on blood pressure monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press. Monit.7, 3\u201318 (2002)."},{"key":"e_1_3_2_27_1","first-page":"S25","volume-title":"J. Hypertens.","author":"O'Brien E","year":"1991","unstructured":"O'Brien E , MeeF, AtkinsN, O'MalleyK: Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J. Hypertens.9(Suppl. 5), S25\u2013S31 (1991)."},{"key":"e_1_3_2_28_1","first-page":"504","volume-title":"Hypertension","author":"White WB","year":"1993","unstructured":"White WB , BersonAS, RobbinsC et al.: National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension21, 504\u2013509 (1993)."},{"key":"e_1_3_2_29_1","first-page":"S43","volume-title":"J. Hypertens.","author":"O'Brien E","year":"1993","unstructured":"O'Brien E , PetrieJ, LittlerWA et al.: The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J. Hypertens.11(Suppl. 2), S43\u2013S63 (1993)."},{"key":"e_1_3_2_30_1","first-page":"840","volume-title":"Am. J. Hypertens.","author":"Tikhonoff V","year":"2003","unstructured":"Tikhonoff V , KuznetsovaT, StolarzK et al.: \u03b2-Adducin polymorphisms, blood pressure and sodium excretion in three European populations. Am. J. Hypertens.16, 840\u2013846 (2003)."},{"key":"e_1_3_2_31_1","first-page":"961","volume-title":"J. Hypertens.","author":"Cwynar M","year":"2005","unstructured":"Cwynar M , StaessenJA, Tich\u00e1M et al.: Epistatic interaction between \u03b1- and \u03b3-adducin influences peripheral and central pulse pressure in White Europeans. J. Hypertens.23, 961\u2013969 (2005)."},{"key":"e_1_3_2_32_1","first-page":"315","volume-title":"Blood Press. Monit.","author":"Fagard RH","year":"1997","unstructured":"Fagard RH , StaessenJA, ThijsL: Optimal definition of daytime and night-time blood pressure. Blood Press. Monit.2, 315\u2013321 (1997)."},{"key":"e_1_3_2_33_1","first-page":"17","volume-title":"High Blood Press.","author":"Thijs L","year":"1992","unstructured":"Thijs L , StaessenJ, FagardR: Analysis of the diurnal blood pressure curve. High Blood Press.1, 17\u201328 (1992)."},{"key":"e_1_3_2_34_1","first-page":"659","volume-title":"Hypertension","author":"Staessen JA","year":"1997","unstructured":"Staessen JA , ThijsL, ByttebierG et al.: Determining the trough-to-peak ratio in parallel-group trials. Hypertension29, 659\u2013667 (1997)."},{"key":"e_1_3_2_35_1","first-page":"942","volume-title":"Hypertension","author":"Staessen JA","year":"1995","unstructured":"Staessen JA , BieniaszewskiL, BuntinxF et al.: The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. Hypertension26, 942\u2013949 (1995)."},{"key":"e_1_3_2_36_1","first-page":"153","volume-title":"Drug Inform. J.","author":"Chuang-Stein C","year":"2000","unstructured":"Chuang-Stein C : Some issues concerning the normalization of laboratory data based on reference ranges. Drug Inform. J.35, 153\u2013156 (2000)."},{"key":"e_1_3_2_37_1","first-page":"606","volume-title":"Bull. Pan. Am. Health Organ.","year":"1990","unstructured":"41st World Medical Assembly: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull. Pan. Am. Health Organ.24, 606\u2013609 (1990)."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1201\/b14127-26"},{"key":"e_1_3_2_39_1","first-page":"1551","volume-title":"J. Hypertens.","author":"Balkestein EJ","year":"2002","unstructured":"Balkestein EJ , WangJG, StruijkerBoudier HAJ et al.: Carotid and femoral intimamedia thickness in relation to three candidate genes in a Caucasian population. J. Hypertens.20, 1551\u20131561 (2002)."},{"key":"e_1_3_2_40_1","first-page":"1680","volume-title":"JAMA","author":"Psaty BM","year":"2002","unstructured":"Psaty BM , SmithNL, HecbertSR et al.: Diuretic therapy, the \u03b1-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA287, 1680\u20131690 (2002)."},{"key":"e_1_3_2_41_1","first-page":"527","volume-title":"Hypertension","author":"Li Y","year":"2005","unstructured":"Li Y , ThijsL, KuznetsovaT et al.: Cardiovascular risk in relation to \u03b1-adducin Gly460Trp polymorphism and systolic pressure. A prospective population study. Hypertension46(3), 527\u2013532 (2005)."},{"key":"e_1_3_2_42_1","first-page":"525","volume-title":"J. Hypertens.","author":"Stolarz K","year":"2003","unstructured":"Stolarz K , StaessenJA, KuznetsovaT et al.: Host and environmental determinants of heart rate and heart rate variability in four European populations. J. Hypertens.21, 525\u2013535 (2003)."},{"key":"e_1_3_2_43_1","volume-title":"J. Hypertens","author":"Kuznetsova T","year":"2005","unstructured":"Kuznetsova T , StaessenJA, BrandE et al.: Sodium excretion as modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J. Hypertens. (2005) (In press)."},{"key":"e_1_3_2_44_1","first-page":"209","volume-title":"J. Hypertens.","author":"Dumas P","year":"2002","unstructured":"Dumas P , KrenV, Krenov\u00e1D, PravenecM, HametP, TremblayJ: Identification and chromosomal localization of ecogenetic components of electrolyte excretion. J. Hypertens.20, 209\u2013217 (2002)."},{"key":"e_1_3_2_45_1","first-page":"437","volume-title":"Ann. Intern. Med.","author":"Cooper RS","year":"2003","unstructured":"Cooper RS : Gene\u2013environment interactions and the etiology of complex disease. Ann. Intern. Med.139, 437\u2013440 (2003)."},{"key":"e_1_3_2_46_1","first-page":"2143","volume-title":"Eur. Heart J.","author":"Schut AFC","year":"2004","unstructured":"Schut AFC , BleuminkGS, StrickerBHC et al.: Angiotensin converting enzyme insertion\/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur. Heart J.25, 2143\u20132148 (2004)."},{"key":"e_1_3_2_47_1","first-page":"510","volume-title":"Occup. Environ. Med.","author":"Staessen JA","year":"2000","unstructured":"Staessen JA , O'BrienET, ThijsL, FagardRH: Modern approaches to blood pressure measurement. Occup. Environ. Med.57, 510\u2013520 (2000)."},{"key":"e_1_3_2_48_1","doi-asserted-by":"crossref","unstructured":"Staessen JA ThijsL ParatiG ManciaG O'BrienET on behalf of the Syst-Eur Investigators: Clinical trials with ambulatory blood pressure monitoring: fewer patients needed?Lancet344 1552\u20131556 (1994).","DOI":"10.1016\/S0140-6736(94)90355-7"},{"key":"e_1_3_2_49_1","first-page":"33","volume-title":"Fundamentals of Clinical Trials","author":"Friedman JM","year":"1985","unstructured":"Friedman JM , FurbergCD, DeMetsDL: Basic study design. In: Fundamentals of Clinical Trials, 2nd ed. Fundamentals of Clinical Trials, PSG Publishing Company Inc., Littleton, Massachusetts, USA, 33\u201350 (1985)."},{"key":"e_1_3_2_50_1","first-page":"443","volume-title":"J. Hypertens.","author":"Staessen JA","year":"1993","unstructured":"Staessen JA , Birkenh\u00e4gerW, BulpittCJ et al.: The relationship between blood pressure and sodium and potassium excretion during the day and at night. J. Hypertens.11, 443\u2013447 (1993)."},{"key":"e_1_3_2_51_1","first-page":"168","volume-title":"Jap. Circ. J.","author":"Kawasaki T","year":"1984","unstructured":"Kawasaki T , UenoM, UezonoK et al.: The renin\u2013angiotensin\u2013aldosterone system and circadian rhythm of urine variables in normotensive and hypertensive subjects. Jap. Circ. J.48, 168\u2013172 (1984)."},{"key":"e_1_3_2_52_1","first-page":"359","volume-title":"Endocrinol. Exp.","author":"Bultasova H","year":"1986","unstructured":"Bultasova H , VeselkovaA, BrodanV, PinskerP: Circadian rhythms of urinary sodium, potassium and some agents influencing their excretion in young borderline hypertensives. Endocrinol. Exp.20, 359\u2013369 (1986)."},{"key":"e_1_3_2_53_1","first-page":"373","volume-title":"Clin. Sci.","author":"Parry EHO","year":"1968","unstructured":"Parry EHO , DolleryCT: Diurnal changes in plasma volume in hypertensive patients: effect of posture and sodium depletion. Clin. Sci.35, 373\u2013380 (1968)."},{"key":"e_1_3_2_54_1","first-page":"1471","volume-title":"Kidney Int.","author":"Manunta P","year":"1998","unstructured":"Manunta P , CusiD, BarlassinaC et al.: \u03b1-Adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int.53, 1471\u20131478 (1998)."},{"key":"e_1_3_2_55_1","first-page":"1629","volume-title":"Lancet","author":"Staessen JA","year":"2003","unstructured":"Staessen JA , WangJ, BianchiG, Birkenh\u00e4gerWH: Essential hypertension. Lancet361, 1629\u20131641 (2003)."},{"key":"e_1_3_2_56_1","first-page":"1003","volume-title":"JAMA","author":"Vasan RS","year":"2002","unstructured":"Vasan RS , BeiserA, LarsonMG, KannelWB, D'AgostinoRB, LevyD: Residual lifetime risk of developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA287, 1003\u20131010 (2002)."},{"key":"e_1_3_2_57_1","first-page":"60","volume-title":"Hypertension","author":"Burt VL","year":"1995","unstructured":"Burt VL , CutlerJA, HigginsM et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension26, 60\u201369 (1995)."},{"key":"e_1_3_2_58_1","first-page":"2420","volume-title":"JAMA","author":"Staessen JA","year":"2003","unstructured":"Staessen JA , KuznetsovaT, StolarzK: Hypertension prevalence and stroke mortality across populations. JAMA289, 2420\u20132422 (2003)."},{"key":"e_1_3_2_59_1","first-page":"2081","volume-title":"J. Hypertens.","author":"Weinehall L","year":"2002","unstructured":"Weinehall L , \u00e4hgrenB, PerssonM et al.: High remaining risk in poorly treated hypertension: the \u201arule of halves\u201b still exist. J. Hypertens.20, 2081\u20132088 (2002)."},{"key":"e_1_3_2_60_1","first-page":"41","volume-title":"J. Hypertens.","author":"Cruickshank JK","year":"2001","unstructured":"Cruickshank JK , MbanyaJC, WilksR et al.: Hypertension in four African-origin populations: current \u201aRule of Halves\u201b, quality of blood pressure control and attributable risk of cardiovascular disease. J. Hypertens.19, 41\u201346 (2001)."},{"key":"e_1_3_2_61_1","first-page":"2022","volume-title":"Lancet","author":"Julius S","year":"2004","unstructured":"Julius S , KjeldsenSE, WeberM et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet363, 2022\u20132031 (2004)."},{"key":"e_1_3_2_62_1","first-page":"544","volume-title":"Am. J. Hypertens.","author":"Julius S","year":"2003","unstructured":"Julius S , KjeldsenSE, BrunnerH et al.: VALUE trial: long-term blood pressure trends in13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens.16, 544\u2013548 (2003)."},{"key":"e_1_3_2_63_1","first-page":"255","volume-title":"Hypertension","author":"Staessen JA","year":"2005","unstructured":"Staessen JA , ThijsL, Birkenh\u00e4gerWH: Noncardiovascular illness as barrier to antihypertensive treatment. Hypertension46, 255\u2013256 (2005)."},{"key":"e_1_3_3_2_1","unstructured":"www.dableducational.org dabl\u00ae Educational Trust website."},{"key":"e_1_3_3_3_1","unstructured":"www.fda.gov\/cder\/offices\/ods\/regs.htm Center for Drug Evaluation and Research website."},{"key":"e_1_3_3_4_1","unstructured":"www.meddramsso.com Medical Dictionary for Regulatory Activities website."},{"key":"e_1_3_3_5_1","unstructured":"www.umc-products.com The UMC website."},{"key":"e_1_3_3_6_1","unstructured":"www.kuleuven.be\/lrd\/about\/mission.html K.U. Leuven R&D website."}],"container-title":["Pharmacogenomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14622416.6.7.755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:04:52Z","timestamp":1715961892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14622416.6.7.755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["10.2217\/14622416.6.7.755"],"URL":"https:\/\/doi.org\/10.2217\/14622416.6.7.755","relation":{},"ISSN":["1462-2416","1744-8042"],"issn-type":[{"value":"1462-2416","type":"print"},{"value":"1744-8042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}